Search

Your search keyword '"Vizimpro (Medication)"' showing total 21 results
Start Over Descriptor "Vizimpro (Medication)"
21 results on '"Vizimpro (Medication)"'

1. Pfizer's tyrosine kinase inhibitor, Vizimpro gets European approval to treat patients with EGFR-mutated NSCLC

Subjects
Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Non-small cell lung cancer -- Drug therapy, Cancer metastasis -- Drug therapy, Phenols (Class of compounds), Tyrosine, Death, Cancer, Lung cancer, Marketing, Small cell lung cancer, Pharmaceuticals and cosmetics industries, Vizimpro (Medication)
Abstract

Pfizer Inc. announced that the European Commission has approved Vizimpro (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic [...]

Published
2019

2. Pfizer announces European Commission approval for Vizimpro

Subjects
Pfizer Inc., Pharmaceutical industry, Drug approval, Non-small cell lung cancer, Phenols (Class of compounds), Cancer metastasis, Small cell lung cancer, Epidermal growth factors, Tyrosine, Lung cancer, Business, News, opinion and commentary, European Union. European Commission, Vizimpro (Medication)
Abstract

Pfizer announced that the European Commission has approved Vizimpro, a tyrosine kinase inhibitor, as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung [...]

Published
2019

3. Pfizer gets positive opinion from EMA committee for Vizimpro to treat NSCLC with EGFR-activating mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Cancer, Lung cancer, Marketing, Small cell lung cancer, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, [...]

Published
2019

4. Pfizer receives positive CHMP opinion for Vizimpro

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Non-small cell lung cancer -- Care and treatment, Cancer metastasis -- Care and treatment, Marketing, Small cell lung cancer, Epidermal growth factors, Lung cancer, Business, News, opinion and commentary, Vizimpro (Medication)
Abstract

Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Vizimpro 45 mg, as monotherapy, be granted marketing [...]

Published
2019

5. Pfizer announces FDA approval for Vizimpro

Subjects
Pfizer Inc., Metastasis -- Drug therapy, Lung cancer, Non-small cell -- Drug therapy, Pharmaceutical industry, Business, News, opinion and commentary, Vizimpro (Medication)
Abstract

Pfizer announced that the FDA has approved Vizimpro, a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor, [...]

Published
2018

6. Summary of opinion1 (initial authorisation) Vizimpro dacomitinib

Subjects
Marketing, Web sites (World Wide Web), Business, international, European Union, Vizimpro (Medication)
Abstract

Amsterdam: European Medicines Agency has issued the following document: 30 Churchill Place * Canary Wharf * London E14 5EU * United Kingdom An agency of the European Union Telephone +44 [...]

Published
2019

7. VIZIMPRO(r) (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Subjects
Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Small cell lung cancer, Marketing, Non-small cell lung cancer, Cancer metastasis, Death, Lung cancer, Phenols (Class of compounds), Tyrosine, General interest, News, opinion and commentary, European Union. European Commission, European Union, Vizimpro (Medication)
Abstract

New York City: Pfizer has issued the following news release: Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO(r) (dacomitinib), a tyrosine kinase inhibitor (TKI), as [...]

Published
2019

8. VIZIMPRO Receives Marketing Authorization in European Union for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Subjects
Pfizer Inc., Pharmaceutical industry, European Union. European Commission, European Union, Vizimpro (Medication)
Abstract

ENPNewswire-April 4, 2019--VIZIMPRO Receives Marketing Authorization in European Union for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 03042019 - [...]

Published
2019

9. VIZIMPRO[R] (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Subjects
Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Small cell lung cancer, Marketing, Non-small cell lung cancer, Cancer metastasis, Death, Lung cancer, Phenols (Class of compounds), Tyrosine, Business, Business, international, European Union. European Commission, European Union, Vizimpro (Medication)
Abstract

NEW YORK -- Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO([R]) (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult [...]

Published
2019

11. Pfizer Receives Positive CHMP Opinion for Vizimpro[R] (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Backup software, Lung cancer, Marketing, Business, Business, international, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

NEW YORK -- Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro[R] (dacomitinib) [...]

Published
2019

12. QIAGEN Receives Approval for EGFR Test in Lung Cancer as Companion Diagnostic in Japan

Subjects
QIAGEN N.V., Pfizer Inc., Biological products industry, Pharmaceutical industry, General interest, News, opinion and commentary, Vizimpro (Medication)
Abstract

HILDEN: QIAGEN has issued the following press release:-QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen(r) [...]

Published
2019

13. U.S. FDA Approves VIZIMPRO[R] (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Subjects
United States. Food and Drug Administration, Pfizer Inc., Metastasis -- Drug therapy, Lung cancer, Small cell -- Drug therapy, Lung cancer, Non-small cell -- Drug therapy, Epidermal growth factor, Pharmaceutical industry, Business, Business, international, Xalkori (Medication), Vizimpro (Medication)
Abstract

Approval Supported by Data from Phase 3 Head-to-Head Study vs. Gefitinib NEW YORK -- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved VIZIMPRO[R] [...]

Published
2018

14. Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050

Subjects
Pfizer Inc., Epidermal growth factors, Pharmaceutical industry, Non-small cell lung cancer, Small cell lung cancer, Tyrosine, Dacomitinib, Phenols (Class of compounds), Cancer metastasis, Editors, Lung cancer, Education, News, opinion and commentary, Vizimpro (Medication)
Abstract

2019 DEC 11 (VerticalNews) -- By a News Reporter-Staff News Editor at Education Letter -- Pfizer Inc. (NYSE: PFE) announced the efficacy and tolerability results from the subgroup analysis of [...]

Published
2019

15. VIZIMPRO® dacomitinib Receives Marketing Authorization in European Union EU for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Subjects
Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Small cell lung cancer, Marketing, Non-small cell lung cancer, Cancer metastasis, Death, Lung cancer, Phenols (Class of compounds), Antineoplastic agents, Anopheles, Tyrosine, Editors, Advertising, marketing and public relations, European Union. European Commission, European Union, Vizimpro (Medication)
Abstract

2019 APR 20 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Pfizer Inc. (NYSE: PFE) announced that the European Commission has approved VIZIMPRO® (dacomitinib), a [...]

Published
2019

16. Vizimpro Receives Marketing Authorization in European Union for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Subjects
Pfizer Inc., Pharmaceutical industry, Small cell lung cancer, Marketing, Drug approval, Non-small cell lung cancer, Labels, Lung cancer, Phenols (Class of compounds), Cancer metastasis, Epidermal growth factors, Tyrosine, Medical research, Chemistry, European Union. European Commission, Vizimpro (Medication)
Abstract

M2 PHARMA-April 8, 2019-Vizimpro Receives Marketing Authorization in European Union for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer (C)2019 M2 COMMUNICATIONS - The European Commission [...]

Published
2019

17. European Commission approves Pfizer's Vizimpro

Subjects
Pfizer Inc., Pharmaceutical industry, Drug approval, Non-small cell lung cancer, Cancer metastasis, Small cell lung cancer, Labels, Epidermal growth factors, Medical research, Lung cancer, Chemistry, European Union. European Commission, Vizimpro (Medication)
Abstract

M2 PHARMA-April 5, 2019-European Commission approves Pfizer's Vizimpro (C)2019 M2 COMMUNICATIONS The European Commission has approved United States-based Pfizer's Vizimpro (dacomitinib) as a monotherapy intended for the first-line treatment of [...]

Published
2019

18. European Commission approves Pfizer's Vizimpro

Subjects
Pfizer Inc., Pharmaceutical industry, Drug approval, Non-small cell lung cancer, Cancer metastasis, Small cell lung cancer, Labels, Epidermal growth factors, Medical research, Lung cancer, Business, European Union. European Commission, Vizimpro (Medication)
Abstract

M2 EQUITYBITES-April 5, 2019-European Commission approves Pfizer's Vizimpro (C)2019 M2 COMMUNICATIONS http://www.m2.com The European Commission has approved United States-based Pfizer's Vizimpro (dacomitinib) as a monotherapy intended for the first-line treatment [...]

Published
2019

19. Pfizer Gets Positive CHMP Opinion for Vizimpro for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Lung cancer, Marketing, Epidermal growth factors, Business, Business, international, Telecommunications industry, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

Pfizer reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, [...]

Published
2019

20. Pfizer Receives Positive CHMP Opinion for Vizimpro for the First-line Treatment of Adult Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Marketing, Cancer metastasis, Small cell lung cancer, Non-small cell lung cancer, Epidermal growth factors, Lung cancer, Chemistry, Vizimpro (Medication)
Abstract

- The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, be granted marketing authorisation [...]

Published
2019

21. Pharmaceutical Times - NICE OK for life-extending Vizimpro in lung cancer - 5/7/2019

Subjects
Pfizer Inc., Pharmaceutical industry, Non-small cell lung cancer -- Care and treatment, Cancer metastasis, Lung cancer, Business, international, Vizimpro (Medication)
Abstract

Pfizer's Vizimpro (dacomitinib) has been recommended as a first-line treatment option for people with locally advanced or metastatic non-small-cell lung cancer (NSCLC). For the complete story see: [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results